Use of Aspirin Versus Clopidogrel Plus Aspirin After Coronary Artery Bypass Graft Surgery

Abstract

Aspirin and clopidogrel together reduce the risk of recurrent thrombosis-related events in patients with acute coronary syndromes or stent revascularization and may reduce thrombosis-induced saphenous vein graft failure. In this retrospective, observational study, 4297 patients were assigned to 2 groups after coronary artery bypass graft surgery, based on medications prescribed at hospital discharge: aspirin only (n = 3318) or aspirin plus clopidogrel (n = 979). At 4-year follow-up, unadjusted survival was similar between the 2 groups (aspirin—clopidogrel, 87.9% vs aspirin-only, 88.8%, P = .43). After statistical adjustment using Cox regression analysis, dual anti-platelet therapy at hospital discharge was not associated with improved survival (odds ratio 1.055, 95% confidence interval 0.7-1.4, P = .72). In propensity score-based, case-matched populations (962 patients each), similar results were obtained (odds ratio 0.996, 95% confidence interval 0.7-1.4, P = .98). In our study population, aspirin plus clopidogrel did not provide survival benefit over treatment with aspirin alone in 4 years after coronary artery bypass graft surgery.

Keywords

aspirin clopidogrel aspirin-clopidogrel combination therapy antiplatelet therapy coronary artery bypass graft surgery

References

Buxton BF , Fuller J. Clinical trials and graft patency data in coronary artery surgery-a 30-year perspective. Heart Lung Circ. 2004;13(suppl 3):S7-S12.

Fitzgibbon GM , Kafka HP , Leach AJ , Keon WJ , Hooper GD , Burton JR Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1997;29:706-707.

. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;337:1859.

. Knatterud GL , Rosenberg Y. , Campeau L. , et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation. 2000;102:144-146.

. Fox KA , Mehta SR , Peters R. , et al. and Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation. 2004;110: 1202-1208.

. Thom T. , Haase N. , Rosamond W. , et al. and American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 ;113:e85-e151.

Desai ND , Cohen EA , Naylor CD , Fremes SE , and Radial Artery Patency Study Investigators. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med. 2004;351:2302-2309.

. Rupprecht HJ , Hamm C. , Ischinger T. , Dietz U. , Reimers J. , Meyer J. Angiographic follow-up results of a randomized study on angioplasty versus bypass surgery (GABI trial). GABI Study Group . Eur Heart J. 1996; 17:1140-1141.

Bourassa MG Fate of venous grafts: the past, the present, and the future. J Am Coll Cardiol. 1991;17: 1081-1083.

10.

. Shuhaiber JH , Evans AN , Massad Mg , Geha AS Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothoracic Surg. 2002;22:387-396.

11.

. Shah PJ , Gordon I. , Fuller J. , et al. Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg. 2003;126: 1972-1977.

12.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348: 1329-1339.

13.

Beinart SC , Kolm P. , Veledar E. , et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol. 2005;46: 761-769.